Haleos Labs (NSE:HALEOSLABS) Beneish M-Score: -1.69 (As of Jul. 08, 2026)


NSE:HALEOSLABS Haleos Labs Ltd NSE:HALEOSLABS
72 GF Score
Price ₹1,612.30
GF Value ₹1,123.78
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Haleos Labs Beneish M-Score?

Haleos Labs NSE:HALEOSLABS -0.50% 72 Beneish M-Score is -1.69 as of Jul. 08, 2026. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,123.78 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 822 Biotechnology companies, Haleos Labs ranks worse than 69.34% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.69 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Haleos Labs's Beneish M-Score or its related term are showing as below:

NSE:HALEOSLABS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.14   Med: -2.39   Max: -1.69
Current: -1.69

During the past 11 years, the highest Beneish M-Score of Haleos Labs was -1.69. The lowest was -3.14. And the median was -2.39.


Haleos Labs Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Haleos Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleos Labs Beneish M-Score Chart

Haleos Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.17 -2.24 -2.63 -2.39 -1.69

Haleos Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.39 0.00 0.00 0.00 -1.69

NSE:HALEOSLABS vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Haleos Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haleos Labs Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haleos Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Haleos Labs's Beneish M-Score falls into.


NSE:HALEOSLABS
72GF Score
Haleos Labs Ltd NSE:HALEOSLABS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleos Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Haleos Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9148+0.528 * 0.9627+0.404 * 3.3851+0.892 * 0.9683+0.115 * 1.1336
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.043819-0.327 * 1.0964
=-1.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹613 Mil.
Revenue was ₹3,338 Mil.
Gross Profit was ₹1,289 Mil.
Total Current Assets was ₹1,631 Mil.
Total Assets was ₹4,544 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,781 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹155 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹1,563 Mil.
Long-Term Debt & Capital Lease Obligation was ₹508 Mil.
Net Income was ₹173 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹372 Mil.
Total Receivables was ₹692 Mil.
Revenue was ₹3,447 Mil.
Gross Profit was ₹1,281 Mil.
Total Current Assets was ₹1,506 Mil.
Total Assets was ₹3,900 Mil.
Property, Plant and Equipment(Net PPE) was ₹2,361 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹150 Mil.
Selling, General, & Admin. Expense(SGA) was ₹59 Mil.
Total Current Liabilities was ₹1,421 Mil.
Long-Term Debt & Capital Lease Obligation was ₹200 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(613.393 / 3337.945) / (692.47 / 3447.235)
=0.183764 / 0.200877
=0.9148

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1281.133 / 3447.235) / (1288.59 / 3337.945)
=0.371641 / 0.386043
=0.9627

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1631.055 + 2781.13) / 4544.084) / (1 - (1505.737 + 2360.733) / 3899.911)
=0.029027 / 0.008575
=3.3851

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3337.945 / 3447.235
=0.9683

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(149.967 / (149.967 + 2360.733)) / (154.689 / (154.689 + 2781.13))
=0.059731 / 0.05269
=1.1336

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 3337.945) / (58.517 / 3447.235)
=0 / 0.016975
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((507.675 + 1562.775) / 4544.084) / ((200.071 + 1420.675) / 3899.911)
=0.455636 / 0.415585
=1.0964

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(173.12 - 0 - 372.235) / 4544.084
=-0.043819

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Haleos Labs has a M-score of -1.69 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.69 mean?
Haleos Labs (NSE:HALEOSLABS) has a Beneish M-Score of -1.69 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Haleos Labs and its competitors. According to the industry distribution chart, Haleos Labs ranks #570 out of 822 companies in the Biotechnology industry, placing it in the top 69.3%.
Is Haleos Labs' Beneish M-Score too high?
Haleos Labs' current Beneish M-Score is -1.69. Based on the distribution chart, Haleos Labs ranks #570 out of 822 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #570 out of 822 companies for Beneish M-Score. This places Haleos Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Haleos Labs and its competitors. Haleos Labs's current Beneish M-Score is -1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,123.78, compared to a current price of ₹1,612.30 — trading 43.5% above its estimated fair value. The current Beneish M-Score is -1.69. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Beneish M-Score is -1.69 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?

Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued. The current stock price of ₹1,612.30 is trading 43.5% above its estimated GF Value™ of ₹1,123.78. GuruFocus considers Haleos Labs to be Significantly Overvalued.

Key valuation signals for NSE:HALEOSLABS:

  • Beneish M-Score: -1.69
  • GF Value™: ₹1,123.78 vs. price of ₹1,612.30 (43.5% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haleos Labs Business Description

Other Exchanges 540679:India
Address Road Number 71, Plot Number 19 - III, Opposite Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad, TG, IND, 500096
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score

Get the complete analysis for NSE:HALEOSLABS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,612.30
Price
₹1,123.78
GF Value